Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
COO — frequently asked questions
Is The Cooper Companies, Inc. overvalued?
In our latest published analysis dated 2026-09-20, COO looks meaningfully undervalued. The price recorded at analysis is 55,3 USD versus our fair value of 78,5 USD; the high endpoint is presented separately as potential value of 92,7 USD. That implies roughly 41.9% upside to fair value at that date.
Our latest published report, analyzed 2026-09-20, gives COO a fair value of 78,5 USD and a potential value of 92,7 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for The Cooper Companies, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy COO now?
Our latest published rating for COO, analyzed 2026-09-20, is Strong Buy. The Cooper Companies, Inc. looks meaningfully undervalued at the analysis-date price of 55,3 USD versus fair value of 78,5 USD; potential value is 92,7 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for COO?
The dedicated bear-case section in our report analyzed 2026-09-20 documents The Cooper Companies, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is COO's rating?
Our latest published rating for COO, analyzed 2026-09-20, is Strong Buy, with a published moat assessment of 6.5/10 (Narrow). It reflects our fair value of 78,5 USD, the potential value of 92,7 USD, and the price recorded at analysis (55,3 USD).
Este informe aún no se ha traducido. Actualice en unos minutos una vez que la cola de traducción se ponga al día.
§1 Resumen ejecutivoEN
Respuesta en 30 segundosStrong Buy
Precio frente a valor
Precio
$55.29
Valor razonable
$78.48
Valor potencial
$92.70
A fecha de
2026-09-18
Por qué puede funcionar
Accelerating global adoption of premium silicone hydrogel daily disposable lenses (MyDay, clariti) across Europe and Asia, expanding revenue per wearer and driving consolidated operating margin expansion above 18.0%.
Qué cambiaría nuestra opinión
European annual revenue growth decelerates below 1.0% YoY alongside sustained euro weakness.
We rate The Cooper Companies a Strong Buy based on durable cash flow compounding in specialty vision care and an attractive 41.94% upside to our Fair value of $78.48.
The house rating is Strong Buy. For an ordinary investor, this means the stock presents exceptional risk-adjusted return potential where predictable operating compounding is available at a favorable entry valuation.2
The report was prepared at a price of $55.29 on September 18, 2026. Against this level, our Fair value stands at $78.48, representing 41.94% upside, while our Potential value reaches $92.70 if expansion accelerates.
The primary risk that would alter this view is deceleration of European revenue growth below 1.0% YoY or consolidated operating margins falling below 14.0%. If optical retail destocking or currency depreciation contracts European volume, cash generation would weaken, slowing debt reduction on $2,783.6M of total debt.2,4,5
The core reason the investment can succeed is CooperVision's high wearer retention and ongoing patient upgrade into premium daily disposable silicone hydrogel contact lenses. This dynamic drives recurring revenue growth of 3.5% to 4.5% and sustained segment operating profit ($729.6M in FY2025), lifting free cash flow and expanding intrinsic value per share toward Fair value.3,5
Resilient Vision Care Compounding
CooperVision generates $2,743.8M in revenue and $729.6M in operating profit, driven by high wearer retention and an ongoing mix shift to silicone hydrogel daily disposables.5
Trading at 11.34x forward earnings, shares offer 41.94% upside to the house Fair value of $78.48, presenting an asymmetric risk-reward profile relative to medtech peers.2
Operating cash flow of $796.1M converts net income at 2.12x, fully covering $362.4M in capex and supporting steady deleveraging of total debt.2,4
Recomendación de la casa
We rate The Cooper Companies a Strong Buy because its dominant daily disposable contact lens franchise generates resilient operating cash flow that is priced at a substantial discount to intrinsic value.5
Descripción general de la empresa
CooperVision is a global manufacturer providing products for contact lens wearers. CooperVision develops, manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. CooperVision designs its products to address vision challenges such as astigmatism, presbyopia and myopia with a broad collection of spherical, toric and multifocal contact lenses. CooperSurgical offers a broad array of products and services focused on fertility and women's health. Its portfolio encompasses more than 600 products and services.
The Cooper Companies, Inc. (Cooper, the company ors the Company) is a global medical device company publicly traded on the Nasdaq (Nasdaq: COO). Cooper operates through two business units, CooperVision and CooperSurgical. The following table presents a summary of its business segment net sales:
§2 Caso bajistaEN
Under a combined macro and operational downturn, euro depreciation and European optical retail softening reduce top-line compounding while Cooper Surgical operating margin remains depressed at 3.22%. With debt service on $2,783.6M of total debt absorbing cash at a 5.59% pre-tax cost of debt, consolidated operating margins compress toward 14.0%, testing historical trough valuation multiples.
The Bear scenario reflects prolonged macroeconomic weakness across European optical retail, adverse foreign currency translation, and aggressive private-label contact lens competition. Downside would be confirmed by gross margin contraction and persistent surgical segment stagnation, impairing earnings growth and compressing valuation multiples.
Cómo puede fallar esta tesis
European contact lens volume contraction and severe euro depreciation
Deceleration of European revenue growth below 1.0% YoY weakens the international geographic penetration pillar and lowers fair value by -6.6%.
FV impact
-6.6%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 12 months
Consolidated operating margin compression driven by surgical segment stagnation and corporate cost expansion
Señales de alerta temprana a vigilar
Los cinco acontecimientos que debilitarían nuestra tesis de inversión.
Volume contraction across European optical retail chains coupled with currency depreciation that impairs international expansion.
Actual:30.6% of FY2025 consolidated revenue ($1,253.2M)
Alerta siBelow 1.0% YoY growth
02
§3 Foso competitivoEN
Narrow
Cooper maintains a narrow economic moat grounded in high switching costs and proprietary designs across Cooper Vision daily disposable contact lenses. Prescribing optometrists exhibit significant behavioral inertia, as refitting patients requires uncompensated chair time and trial lenses. Silicone hydrogel formulations in MyDay and clariti create tangible clinical barriers that protect segment profitability ($729.6M operating profit in FY2025). However, reported ROIC of 4.22% remains below the 7.67% WACC, weighed down by historical acquisition goodwill of $3,853.4M, preventing a wide moat classification.
Beneficio económico
While Cooper Vision generates strong cash earnings ($729.6M segment operating profit), consolidated invested capital remains weighed down by $3,853.4M in goodwill, keeping reported ROIC below WACC of 7.67%.1,5
6.5/ 10
Narrow
Sources of advantage
01switching_costs — Optometrist prescribing habits and wearer reluctance to switch contact lens modalities support high customer retention and recurring demand across Cooper Vision's $2,743.8M revenue base.Moderate
02intangible_assets — Proprietary silicone hydrogel patents and specialized manufacturing techniques for toric and multifocal lenses sustain gross profit of $2,682.1M on $4,092.4M revenue (65.54% gross margin).
Amenazas conocidas al foso
Amenaza
Severidad
Cronograma
Mitigación
Retail optical private-label competition and direct-to-consumer alternatives
medium
24-36 months
Continuous innovation in premium toric and multifocal silicone hydrogel daily modalities that optical chains cannot replicate with generic lines.
Foreign exchange volatility in key European distribution regions
The highlighted cell is Fair value when every assumption sits at its base level ($78.48). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $500.4M after modeled reinvestment of $0, with terminal value at 39.3% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
Core vision care revenue expands at a moderate pace aligned with demographic correction needs
Consolidated operating margins remain defensive within historical ranges
Surplus cash flow is directed toward continuous debt paydown
The Base case envisions steady compounding driven by ongoing conversion to premium daily disposable contact lenses, defensive gross margins, and gradual deleveraging. Performance tracks toward Fair value of $78.48, supported by stable replacement demand across optometry networks. The thesis would be challenged if European revenue decelerates or if surgical segment margins fail to recover.
Maintain Strong Buy; Maintain position weighting and confirm international optical retail volume momentum at the subsequent quarterly checkpoint.
Disparador: Consolidated revenue and diluted earnings exceeding consensus upper bounds driven by accelerated daily disposable adoption
Outperformance confirms market share gains in premium silicone hydrogel lenses and validates operating leverage toward Fair value of $78.48.
En línea
Maintain Strong Buy; Hold existing allocation, verify surgical segment margin stabilization, and monitor working capital discipline.
Disparador: Quarterly revenue and earnings matching consensus targets with stable gross margins
In-line execution reaffirms steady compounding thesis and supports ongoing convergence toward Fair value of $78.48.
Fallo
Downgrade to Buy; Re-evaluate surgical segment cost integration and reassess position sizing if margin contraction persists across consecutive reporting periods.
Management balanced capital deployment in FY2025 between $362.4M in manufacturing capex, $290.1M in share buybacks, and net debt reduction of $79.9M, steadily deleveraging total debt of $2,783.6M.
Reported GAAP return on invested capital of 4.22% is suppressed by $3,853.4M in goodwill from past acquisitions, masking underlying operating cash generation.
Reported ROIC of 4.22% trails WACC of 7.67%, though core vision operations generate $729.6M in operating profit on tangible assets.
Vision care franchise generates superior operating profitability relative to surgical instruments
Cooper Vision achieved 26.59% operating margin ($729.6M operating profit on $2,743.8M revenue) compared to Cooper Surgical's 3.22% operating margin ($43.4M on $1,348.6M revenue).
Consolidated margin expansion depends heavily on surgical segment turnaround and sustained daily disposable mix shifts in vision care.
Operating cash generation comfortably covers annual debt service
Operating cash flow of $796.1M supports $100.0M of annual and debt service on total debt of $2,783.6M.
Ingresos más recientes4092,4 M US$CAGR de ingresos +8,5 %
Margen operativo16,7 %10 periodos fiscales
Flujo de caja libre más reciente433,7 M US$FY2025
Deuda neta2673 M US$FY2025
Desglose de la cuenta de resultadosCómo la escala del negocio se convierte en beneficio declarado.
StockMarketAgent.AI
Ingresos4092,4 M US$Coste de ventas−1410,3 M US$Beneficio bruto2682,1 M US$Gastos operativos−1999,2 M US$Beneficio operativo682,9 M US$Partidas no operativas e impuestos−308 M US$Beneficio neto374,9 M US$
Datos del historial financiero
Ingresos
4.092.400.000 US$
Coste de ventas
1.410.300.000 US$
Beneficio bruto
2.682.100.000 US$
Gastos operativos
1.999.200.000 US$
Beneficio operativo
682.900.000 US$
Partidas no operativas e impuestos
-308.000.000 US$
Beneficio neto
374.900.000 US$
Resumen del balanceCómo se mantienen y financian los activos declarados en el período seleccionado.
StockMarketAgent.AI
Composición de activosFinanciado por
Activos totales12,4 mil M US$Efectivo110,6 M US$Activos corrientes2106,4 M US$Pasivos totales4155,7 M US$Pasivos corrientes1112,8 M US$Patrimonio neto8239,1 M US$
Datos del desglose del balance
Activos totales
12.394.800.000 US$
Efectivo
110.600.000 US$
Activos corrientes
2.106.400.000 US$
Pasivos totales
4.155.700.000 US$
Pasivos corrientes
1.112.800.000 US$
Patrimonio neto
8.239.100.000 US$
Puente de flujo de cajaCómo el flujo de caja operativo se convirtió en flujo de caja libre en FY2025.
StockMarketAgent.AI
Conciliación del flujo operativo
Beneficio neto374,9 M US$Depreciación y amortización+377,4 M US$Compensación basada en acciones+70,5 M US$Otros ajustes operativos−26,7 M US$Flujo de caja operativo796,1 M US$
Conciliación del efectivo inicial al final
Efectivo inicial107,7 M US$Flujo de caja operativo+796,1 M US$Flujo de inversión−372,9 M US$Flujo de financiación−425,9 M US$Efecto del tipo de cambio+5,6 M US$Efectivo final110,6 M US$
796,1 M US$ − 362,4 M US$Flujo de caja libre 433,7 M US$
Datos del puente de flujo de caja
Beneficio neto
374.900.000 US$
Entrada operativa
822.800.000 US$
Depreciación y amortización
377.400.000 US$
Compensación basada en acciones
70.500.000 US$
Flujo de caja operativo
796.100.000 US$
Salida operativa
26.700.000 US$
Efectivo disponible
909.400.000 US$
Efectivo inicial
107.700.000 US$
Efecto del tipo de cambio
5.600.000 US$
Salida de inversión
372.900.000 US$
Capex
362.400.000 US$
Otras actividades de inversión
10.500.000 US$
Salida de financiación
425.900.000 US$
Recompras de acciones
290.100.000 US$
Amortización neta de deuda
79.900.000 US$
Otras actividades de financiación
55.900.000 US$
Efectivo final
110.600.000 US$
Flujo de inversión
-372.900.000 US$
Flujo de financiación
-425.900.000 US$
Ingresos por segmento operativoProporción de los ingresos totales de 2025-10-31.
4092,4 M US$Ingresos totales
Ingresos por segmento operativoProporción
Cooper Vision2743,8 M US$67 %+5,2 % interanual
Cooper Surgical1348,6 M US$33 %+4,9 % interanual
Fuente: SEC EDGAR · Presentado 2025-12-05 · SEC EDGAR
Datos de composición de ingresos: Ingresos por segmento operativo
Ingresos por segmento operativo
Ingresos
Proporción
interanual
Cooper Vision
2743,8 M US$
67 %
5,2 %
Cooper Surgical
1348,6 M US$
33 %
4,9 %
Ingresos por regiónProporción de los ingresos totales de 2025-10-31.
4092,4 M US$Ingresos totales
Ingresos por regiónProporción
United States2054 M US$50,2 %+4,5 % interanual
Europe1253,2 M US$30,6 %+8,4 % interanual
Rest Of The World785,2 M US$19,2 %+1,5 % interanual
Fuente: SEC EDGAR · Presentado 2025-12-05 · SEC EDGAR
Datos de composición de ingresos: Ingresos por región
Ingresos por región
Ingresos
Proporción
interanual
United States
2054 M US$
50,2 %
4,5 %
Europe
1253,2 M US$
30,6 %
8,4 %
Rest Of The World
785,2 M US$
19,2 %
1,5 %
Ingresos y beneficiosCómo la escala del negocio se convierte en beneficio declarado.
Efectivo y deudaLiquidez disponible frente al endeudamiento total.
Generación de efectivoFlujo de caja operativo frente al flujo de caja libre.
RentabilidadEvolución de los márgenes bruto, operativo y neto.
Datos financieros puntuales utilizados en el análisis del 2026-09-20.
Datos del historial financiero
Período
Ingresos
EBITDA
Beneficio neto
Flujo de caja operativo
Flujo de caja libre
Capex
Depreciación y amortización
Compensación basada en acciones
Recompras de acciones
Dividendos pagados
Emisión neta de deuda
Flujo de inversión
Flujo de financiación
Efectivo inicial
Efectivo final
Efectivo e inversiones
Deuda total
Margen operativo
ROIC
WACC
Diferencial ROIC−WACC
2016-10-31
1966,8 M US$
520,1 M US$
273,9 M US$
509,6 M US$
357 M US$
152,6 M US$
198,3 M US$
29,9 M US$
0 US$
2,9 M US$
—
-418,7 M US$
-1,4 M US$
—
100,8 M US$
100,8 M US$
1333,7 M US$
16,5 %
—
5,0 %
—
2017-10-31
2139 M US$
615,8 M US$
372,9 M US$
593,6 M US$
466,4 M US$
127,2 M US$
188,4 M US$
37,2 M US$
55 M US$
2,9 M US$
—
-381,3 M US$
-227,9 M US$
100,8 M US$
88,8 M US$
88,8 M US$
1172,7 M US$
20,1 %
—
5,4 %
—
2018-10-31
2532,8 M US$
689,7 M US$
139,9 M US$
668,9 M US$
475,3 M US$
193,6 M US$
275,1 M US$
43,2 M US$
0 US$
2,9 M US$
—
-1517,5 M US$
844,4 M US$
88,8 M US$
80,2 M US$
80,2 M US$
2022,8 M US$
15,9 %
—
5,9 %
—
2019-10-31
2653,4 M US$
826,2 M US$
466,7 M US$
713,2 M US$
421,1 M US$
292,1 M US$
280,8 M US$
35,1 M US$
156,1 M US$
3 M US$
—
-351,3 M US$
-351,4 M US$
80,2 M US$
89,5 M US$
89 M US$
1826,3 M US$
20,6 %
—
5,3 %
—
2020-10-31
2430,9 M US$
590,4 M US$
238,4 M US$
486,6 M US$
176,2 M US$
310,4 M US$
287,1 M US$
37,6 M US$
47,8 M US$
3 M US$
—
-364,5 M US$
-95,5 M US$
89,5 M US$
116,8 M US$
115,9 M US$
2063,3 M US$
12,8 %
—
3,9 %
—
2021-10-31
2922,5 M US$
823,9 M US$
2944,7 M US$
738,6 M US$
524,2 M US$
214,4 M US$
309,3 M US$
43,8 M US$
24,8 M US$
3 M US$
—
-450,3 M US$
-311,4 M US$
116,8 M US$
96,6 M US$
95,9 M US$
1481 M US$
17,3 %
—
4,7 %
—
2022-10-31
3308,4 M US$
878,7 M US$
385,8 M US$
692,4 M US$
450,4 M US$
242 M US$
346,1 M US$
54,2 M US$
78,5 M US$
3 M US$
1278,8 M US$
-1831,2 M US$
1193,7 M US$
96,6 M US$
138,6 M US$
138,2 M US$
2763,4 M US$
15,3 %
—
7,0 %
—
2023-10-31
3593,2 M US$
885,9 M US$
294,2 M US$
607,5 M US$
215 M US$
392,5 M US$
367,7 M US$
62,1 M US$
0 US$
3 M US$
-180,8 M US$
-449 M US$
-173,9 M US$
138,6 M US$
120,9 M US$
120,9 M US$
2569,2 M US$
14,8 %
—
8,0 %
—
2024-10-31
3895,4 M US$
1071,7 M US$
392,3 M US$
709,3 M US$
288,1 M US$
421,2 M US$
375,1 M US$
75,1 M US$
0 US$
0 US$
5,6 M US$
-764,6 M US$
39,2 M US$
120,9 M US$
107,7 M US$
107,6 M US$
2583,7 M US$
18,1 %
—
7,3 %
—
2025-10-31
4092,4 M US$
1053,4 M US$
374,9 M US$
796,1 M US$
433,7 M US$
362,4 M US$
377,4 M US$
70,5 M US$
290,1 M US$
0 US$
-79,9 M US$
-372,9 M US$
-425,9 M US$
107,7 M US$
110,6 M US$
110,6 M US$
2783,6 M US$
16,7 %
—
7,4 %
—
§9 Comparación de valoración con pares
Valor razonableReport-date price
The Cooper Companies, Inc.COO
Precio / valor razonable
Valor razonable78,48 US$Report-date price55,29 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión62 / 100
Align Technology Inc.ALGN
Precio / valor razonable
Valor razonable121,31 US$Report-date price147,61 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión55 / 100
Solventum CorporationSOLV
Precio / valor razonable
Valor razonable103,66 US$Report-date price86,57 US$
Fecha de evaluación
Ventaja competitivaNarrow
Cuadro de mando de inversión57 / 100
The Cooper Companies, Inc.COO
Precio / valor razonable
Valor razonable78,48 US$Report-date price55,29 US$
The Cooper Companies Inc. (COO) trades at 11.3x forward earnings against a peer median of 12.0x. Its EV/EBITDA of 14.1x compares with a peer median of 13.9x. The comparison uses 4 peers: Align Technology Inc., Solventum Corporation, Intuitive Surgical Inc. and Baxter International Inc., as of 2026-09-19 to 2026-09-20.
§10 Industria y cicloEN
Fase del ciclo
Expansion
Annual capital expenditure of $362.4M represents 8.86% of revenue, supporting automated daily disposable contact lens manufacturing lines in line with industry capex-to-depreciation benchmarks of 0.80x.4
Ciclo alcista
Accelerating global conversion from reusable lenses to premium single-use daily disposables, paired with rising worldwide myopia prevalence and demographic expansion in presbyopia treatments.
Ciclo bajista
Optical retail destocking, consumer trade-down toward private label lenses during macroeconomic slowdowns, and adverse foreign exchange translation across European markets.
Tendencias seculares
Tendencia
Impacto
Nota
Global shift toward daily disposable silicone hydrogel contact lenses
positive
Wearers steadily upgrade to single-use modalities for ocular health and convenience, expanding annual revenue per patient.
Rising global myopia diagnosis and pediatric myopia management
positive
Increased screen time drives worldwide myopia rates, sustaining long-term international volume expansion across Europe and Asia.
Consolidation of optical retail chains and private-label proliferation
negative
Large retail optical groups exert bargaining power on lens manufacturers, pressuring wholesale margins on standard spherical designs.
Posicionamiento
Cooper occupies a well-insulated position as a leading global supplier of specialty toric and multifocal lenses, shielding it from standard spherical commodity pricing.
§11 Gestión de posiciónEN
Tamaño de posición
4-6%
Non-discretionary vision care demand, robust operating cash flow, and substantial valuation discount support an above-benchmark weighting.
Riesgo
Risk is mitigated by non-discretionary wearer replacement habits, recurring revenue in daily disposables, and ongoing debt paydown from annual operating cash flow of $796.1M.
CooperVision's high customer retention and daily disposable mix shift support durable 3.5% to 4.5% top-line growth and resilient operating cash generation.5
Valuation Opportunist
Buy
Trading at 11.34x forward earnings, shares sit well below the house Fair value of $78.48, providing a 41.94% upside margin of safety.2
Risk-Conscious / Defensive
Buy
Non-discretionary vision care demand and $796.1M in operating cash flow comfortably support debt service on $2,783.6M of total debt.2,4
§14 Recomendación finalEN
Acción
Compra fuerte
We recommend a Strong Buy on The Cooper Companies based on durable cash compounding from CooperVision's daily disposable contact lens franchise, trading at a 29.55% discount to our Fair value of $78.48.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Working capital deterioration or contact lens inventory build reducing cash available for debt service on $2,783.6M total debt.
Actual:$796.1M in FY2025
Alerta siBelow $600.0M
Moderate
03cost_advantage — High-volume automated daily disposable manufacturing facilities in the United Kingdom and Costa Rica yield efficient per-unit production economics across global distribution channels.Narrow
medium
12-18 months
Natural currency hedging via European operational infrastructure and diversified rest-of-world revenue streams of $785.2M.5
The Bull case models accelerated market share gains in specialty silicone hydrogel daily lenses across Europe and Asia, accompanied by operational integration in Cooper Surgical that lifts segment margins. This outcome delivers Potential value of $92.70 as valuation multiples expand. Slower adoption of daily modalities would disconfirm this trajectory.
Por qué importa
Europe generates substantial consolidated sales; sustained growth confirms geographic penetration while weakness signals macro drag.
03
Métrica:
Cooper Surgical operating profitability
ActualConstrained by integration expenses and operational restructuring
Por qué importa
Surgical margin expansion is required to alleviate the profitability drag on consolidated operating results.
